(2) The administration of the anti-diabetic drug pioglitazone induces DMR in TKI-insensitive CML patients by activating the proliferator-activated receptor γ (PPARγ) signaling pathway and thereby eradicating CML stem cells [40]. The gene discussed is PPARG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.